TISIDB

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm.
Domain	PF00685 Sulfotransferase domain
Function	Sulfotransferase that utilizes 3'-phospho-5'-adenylyl sulfate (PAPS) as sulfonate donor to catalyze the sulfate conjugation of estradiol and estrone. May play a role in the regulation of estrogen receptor activity by metabolizing free estradiol. Maximally sulfates beta-estradiol and estrone at concentrations of 20 nM. Also sulfates dehydroepiandrosterone, pregnenolone, ethinylestradiol, equalenin, diethylstilbesterol and 1-naphthol, at significantly higher concentrations; however, cortisol, testosterone and dopamine are not sulfated.

> Gene Ontology [ TOP ]
Biological Process	GO:0006790 sulfur compound metabolic process GO:0008202 steroid metabolic process GO:0008210 estrogen metabolic process GO:0009116 nucleoside metabolic process GO:0009119 ribonucleoside metabolic process GO:0009150 purine ribonucleotide metabolic process GO:0010817 regulation of hormone levels GO:0033865 nucleoside bisphosphate metabolic process GO:0033875 ribonucleoside bisphosphate metabolic process GO:0034032 purine nucleoside bisphosphate metabolic process GO:0034035 purine ribonucleoside bisphosphate metabolic process GO:0034754 cellular hormone metabolic process GO:0042278 purine nucleoside metabolic process GO:0042445 hormone metabolic process GO:0045444 fat cell differentiation GO:0045598 regulation of fat cell differentiation GO:0045600 positive regulation of fat cell differentiation GO:0046128 purine ribonucleoside metabolic process GO:0050427 3'-phosphoadenosine 5'-phosphosulfate metabolic process GO:0051923 sulfation GO:1901657 glycosyl compound metabolic process
Molecular Function	GO:0004062 aryl sulfotransferase activity GO:0004304 estrone sulfotransferase activity GO:0005496 steroid binding GO:0008146 sulfotransferase activity GO:0016782 transferase activity, transferring sulfur-containing groups GO:0047894 flavonol 3-sulfotransferase activity GO:0050294 steroid sulfotransferase activity
Cellular Component	-

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa00140 Steroid hormone biosynthesis
Reactome	R-HSA-211859: Biological oxidations R-HSA-156584: Cytosolic sulfonation of small molecules R-HSA-1430728: Metabolism R-HSA-156580: Phase II conjugation

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between SULT1E1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of SULT1E1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	NA/NS	NA/NS
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	Second most enriched score: 0.51	Sensitive to T cell-mediated killing
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of SULT1E1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	0	1
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0	1
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	0	1
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	-0.545	0.441
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0.736	0.534
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	-2.156	0.138
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.073	0.938
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	-0.147	0.935
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.217	0.907
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	-0.613	0.368
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	-0.613	0.512
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	0.681	0.124

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of SULT1E1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	7.4	6.8	0.6	1
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	7.4	8.5	-1.1	1
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	4.8	5.9	-1.1	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	7.7	9.1	-1.4	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	6.2	-6.2	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	11.1	-11.1	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	5.3	0	5.3	0.507
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	9.1	0	9.1	0.519
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of SULT1E1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of SULT1E1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by SULT1E1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of SULT1E1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of SULT1E1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between SULT1E1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	SULT1E1
Name	sulfotransferase family 1E, estrogen-preferring, member 1
Aliases	STE; sulfotransferase, estrogen-preferring; EST-1; ST1E1; estrone sulfotransferase; sulfotransferase 1E1; Es ......
Chromosomal Location	4q13.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting SULT1E1 collected from DrugBank database.

> Drugs from DrugBank database

[ TOP ]

Details on drugs targeting SULT1E1.

ID	Name	Drug Type	Targets	#Targets
DB01176	Cyclizine	Small Molecule	HRH1, SULT1E1	2
DB01812	Adenosine-3'-5'-Diphosphate	Small Molecule	HS3ST1, HS3ST3A1, NDST1, RNASE1, RNASE2, SULT1A1, SULT1B1, SULT1E1 ......	10
DB02902	3'-Phosphate-Adenosine-5'-Phosphate Sulfate	Small Molecule	SULT1E1	1
DB03346	3,5,3',5'-Tetrachloro-Biphenyl-4,4'-Diol	Small Molecule	SULT1E1	1

Browse SULT1E1